Chemoinformaics analysis of 2,3-EPOXYGERIANIAL
| Molecular Weight | 168.236 | nRot | 4 |
| Heavy Atom Molecular Weight | 152.108 | nRig | 5 |
| Exact Molecular Weight | 168.115 | nRing | 1 |
| Solubility: LogS | -2.3 | nHRing | 1 |
| Solubility: LogP | 2.284 | No. of Aliphatic Rings | 1 |
| Acid Count | 0 | No. of Aromatic Rings | 0 |
| Base Count | 0 | No. of Aliphatic Carbocycles Rings | 0 |
| Atoms Count | 28 | No. of Aliphatic Hetero Cycles | 1 |
| No. of Heavy Atom | 12 | No. of Aromatic Carbocycles | 0 |
| nHetero | 2 | No. of Aromatic Hetero Cycles | 0 |
| nBridge Head | 0 | No. Saturated Carbocycles | 0 |
| No. of Hydrogen atom | 16 | No. of Saturated Hetero Cycles | 1 |
| No. of Carbon atom | 10 | No. of Saturated Rings | 1 |
| No. of Nitrogen atom | 0 | No. of Arom Atom | 0 |
| No. of Oxygen atom | 2 | No. of Arom Bond | 0 |
| nHA | 2 | APOL | 28.9727 |
| nHD | 0 | BPOL | 18.6553 |
| QED | 0.365 |
| Synth | 4.144 |
| Natural Product Likeliness | 2.871 |
| NR-PPAR-gamma | 0.63 |
| Lipinski | Accepted |
| Pfizer | Accepted |
| GSK | Accepted |
| Golden Triangle | Rejected |
| Pgp-inh | 0.01 |
| Pgp-sub | 0.002 |
| HIA | 0.007 |
| CACO-2 | -4.435 |
| MDCK | 0.0000235 |
| BBB | 0.989 |
| PPB | 0.529225 |
| VDSS | 2.284 |
| FU | 0.370689 |
| CYP1A2-inh | 0.063 |
| CYP1A2-sub | 0.314 |
| CYP2c19-inh | 0.031 |
| CYP2c19-sub | 0.813 |
| CYP2c9-inh | 0.012 |
| CYP2c9-sub | 0.083 |
| CYP2d6-inh | 0.008 |
| CYP2d6-sub | 0.211 |
| CYP3a4-inh | 0.045 |
| CYP3a4-sub | 0.263 |
| CL | 16.029 |
| T12 | 0.56 |
| hERG | 0.018 |
| Ames | 0.733 |
| ROA | 0.016 |
| SkinSen | 0.955 |
| Carcinogencity | 0.331 |
| EI | 0.968 |
| Respiratory | 0.488 |
| NR-Aromatase | 0.035 |
| Antiviral | No |
| Prediction | 0.921814 |